Abstract
Immune checkpoints (ICPs) consist of paired receptor-ligand molecules that exert inhibitory or stimulatory effects on immune defense, surveillance, regulation, and self-tolerance. ICPs exist in both membrane and soluble forms in vivo and in vitro. Imbalances between inhibitory and stimulatory membrane-bound ICPs (mICPs) in malignant cells and immune cells in the tumor immune microenvironment (TIME) have been well documented. Blockades of inhibitory mICPs have emerged as an immense breakthrough in cancer therapeutics. However, the origin, structure, production regulation, and biological significance of soluble ICPs (sICPs) in health and disease largely remains elusive. Soluble ICPs can be generated through either alternative mRNA splicing and secretion or protease-mediated shedding from mICPs. Since sICPs are found in the bloodstream, they likely form a circulating immune regulatory system. In fact, there is increasing evidence that sICPs exhibit biological functions including (1) regulation of antibacterial immunity, (2) interaction with their mICP compartments to positively or negatively regulate immune responses, and (3) competition with their mICP compartments for binding to the ICP blocking antibodies, thereby reducing the efficacy of ICP blockade therapies. Here, we summarize current data of sICPs in cancer and infectious diseases. We particularly focus on sICPs in COVID-19 and HIV infection as they are the two ongoing global pandemics and have created the world’s most serious public health challenges. A “storm” of sICPs occurs in the peripheral circulation of COVID-19 patients and is associated with the severity of COVID-19. Similarly, sICPs are highly dysregulated in people living with HIV (PLHIV) and some sICPs remain dysregulated in PLHIV on antiretroviral therapy (ART), indicating these sICPs may serve as biomarkers of incomplete immune reconstitution in PLHIV on ART. We reveal that HIV infection in the setting of alcohol abuse exacerbates sICP dysregulation as PLHIV with heavy alcohol consumption have significantly elevated plasma levels of many sICPs. Thus, both stimulatory and inhibitory sICPs are present in the bloodstream of healthy people and their balance can be disrupted under pathophysiological conditions such as cancer, COVID-19, HIV infection, and alcohol abuse. There is an urgent need to study the role of sICPs in immune regulation in health and disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Alcohol Abuse and Alcoholism (grant number UH2AA026218 to Q. Y.); the Bill and Melinda Gates Foundation (grant number OPP1035237 to Q. Y.); the Indiana Biobank and the Indiana Clinical and Translational Sciences Institute funded by the NIH (grant number UL1TR002529); and the National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. Dr. Khalili was also in part supported by the National Institute of Alcohol Abuse and Alcoholism (grant number K24AA022523).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study Subjects and Ethical Considerations. This study was performed with the approval of the Institutional Review Board at Indiana University School of Medicine and University of California San Francisco. Blood samples were drawn after each participant provided a written informed consent form.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ALD
- alcohol-associated liver disease
- APC
- antigen-presenting cell
- ART
- antiretroviral therapy
- BTLA
- B- and T-lymphocyte attenuator
- CTLA-4
- cytotoxic T-lymphocyte-associated protein 4
- GITR
- glucocorticoid-induced tumor necrosis factor receptor-related protein
- GITRL
- glucocorticoid-induced tumor necrosis factor receptor-ligand
- HBV
- hepatitis B virus
- HC
- healthy control
- HCC
- hepatocellular carcinoma
- HIV
- human immunodeficiency virus
- HVEM
- herpesvirus entry mediator
- ICP
- immune checkpoint
- ICOS
- inducible T-cell costimulator
- LAG-3
- lymphocyte-activation gene 3
- LIGHT
- homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes
- mICP
- membrane-bound immune checkpoint
- PD-1
- programmed death 1
- PD-L1
- programmed death-ligand 1
- PLHIV
- people living with HIV
- sICP
- soluble immune checkpoint
- TB
- tuberculosis
- TCR
- T cell receptor
- TIM-3
- T-cell immunoglobulin and mucin domain 3
- TIME
- tumor immune microenvironment
- TNFRSF
- tumor necrosis factor receptor superfamily
- TLR-2
- Toll-like receptor-2